NCT06040970View on ClinicalTrials.gov

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

September 7, 2026

Study Completion Date

September 7, 2026

Conditions
Ovarian CancerMalignant Neoplasm of Uterus
Interventions
DRUG

Sacituzumab

"Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg"

DRUG

Cisplatin

Cisplatin 70 mg/m2 IV

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER